(NASDAQ: APVO) Aptevo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.38%.
Aptevo Therapeutics's earnings in 2026 is -$27,924,000.On average, 3 Wall Street analysts forecast APVO's earnings for 2026 to be -$30,669,884, with the lowest APVO earnings forecast at -$29,467,143, and the highest APVO earnings forecast at -$31,571,939. On average, 3 Wall Street analysts forecast APVO's earnings for 2027 to be -$27,276,242, with the lowest APVO earnings forecast at -$26,206,585, and the highest APVO earnings forecast at -$28,078,484.
In 2028, APVO is forecast to generate -$22,929,329 in earnings, with the lowest earnings forecast at -$22,030,140 and the highest earnings forecast at -$23,603,721.